Vista signs licensing agreements with Harvard University and Nanosys
Under terms of the agreements, Vista has secured the exclusive, worldwide rights for the use of nanowires for the detection of biomarkers associated with organ or tissue damage,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The FDA has previously approved this improved formulation of Epoprostenol for Injection (1.5mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with
The multi-dose, placebo-controlled, three-period cross-over study, included 20 stable asthmatic patients. LAS 100977 demonstrated 24 hour bronchodilation and sustained efficacy during multiple dose administrations with no significant increase